Miercoles 07/07/11, ISM no manufacturero

[admin]

Miercoles

Eventos economicos

Solicitudes de hipotecas
Ventas de tiendas
ISM no manufacturero
Subasta de bonos
Libro rojo


MBA Purchase Applications
7:00 AM ET


Challenger Job-Cut Report
7:30 AM ET


ICSC-Goldman Store Sales
7:45 AM ET


Redbook
8:55 AM ET


ISM Non-Mfg Index
10:00 AM ET


4-Week Bill Auction
11:30 AM ET

[admin]

Yen up 80.88

El hang Seng -0.43%, Australia -0.32%, el Nikkei +0.03%, Korea -0.23%, el Shanghai C. -0.45%

Euro up 1.4438

Los futures del Dow Jones 3 puntos al alza.

[admin]

Copper July 05,21:19
Bid/Ask 4.3083 - 4.3105
Change -0.0006 -0.01%
Low/High 4.2955 - 4.3111
Charts

Nickel July 05,21:17
Bid/Ask 10.5591 - 10.5927
Change -0.0113 -0.11%
Low/High 10.5478 - 10.6045
Charts

Aluminum July 05,21:19
Bid/Ask 1.1427 - 1.1428
Change -0.0003 -0.03%
Low/High 1.1404 - 1.1463
Charts

Zinc July 05,21:18
Bid/Ask 1.0765 - 1.0783
Change -0.0010 -0.09%
Low/High 1.0739 - 1.0824
Charts

Lead July 05,21:19
Bid/Ask 1.2109 - 1.2131
Change +0.0000 +0.00%
Low/High 1.2091 - 1.2199

[admin]

Mas transparencia.

Por primera vez China permitira que la SEC investigue las companias Chinas.

[admin]

Para los pequenios negocios en US la recesion no ha terminado. El 78% de ellos dice que la recesion no ha terminado, y muchos esperan que continue hasta el proximo anio. En Mayo y por tercer mes consecutivo, el optimismo de los duenios de pequenios negocios declino.

El 70% de ellos no tiene planes de expandir o contratar mas personal en los proximos 12 meses, citan la incertidumbre economica y las presiones inflacionarias como los motivos para no contratar personal y para no invertir mas.

For Small Businesses, Recession Isn't Over

By DANA MATTIOLI And SARAH E. NEEDLEMAN
Many big public companies are likely to report strong second-quarter profits, but that isn't the story on Main Street, where small businesses are grappling with jittery customers, rising costs and tight credit.

BleachSafe Towel founder Morris E. Sitt said it's hard to get proper financing. Mr. Sitt, seated, talks to a salesman in New York.
The owners of many small businesses say economic uncertainty and inflationary pressures have led them to delay hiring and capital expenditures. Seventy percent have no plans to expand their staffs over the next 12 months, according to a recent U.S. Bancorp survey of 1,004 U.S. companies with annual revenue of $10 million or less.

While about half projected higher revenue a year from now, 78% said the U.S. economy is still in a recession, and many expected it to remain there next year. In May, for the third month in a row, the optimism index of the National Federation of Independent Business declined.

At big public companies, cost-cutting and a rebound in sales, particularly overseas, have provided a boost. But because small businesses account for more than half of private-sector employment and gross domestic product, their owners' caution bodes ill for the broader economic recovery.

Last year, Tribute Inc., a developer of inventory-management programs, thought it was seeing a rebound when the time required to close deals improved. But by the end of the year, sales had leveled off and the recovery had faded. Now, getting new contracts across the finish line is taking as long as six months.

"Given what our customers perceive as a flattening in the economy, they're being very cautious on capital expenditures," says Tim Reynolds, president of Tribute, which is based in Hudson, Ohio, and sells its software to small industrial distributors. Tribute is continuing to require its 35 employees to take a day of unpaid vacation every month, a policy it implemented during the recession, as it waits for sales to pick up. Mr. Reynolds is also delaying investment, putting off buying software that would help him manage his sales prospects and customers but could cost as much as $50,000.

"Small businesses aren't hemorrhaging, but they're still waiting for that significant uptick," says Todd McCracken, chief executive of the National Small Business Association.

One issue is credit. Small businesses are still having a hard time getting bank loans. Lending to them fell 2.4% in the first quarter, the Small Business Administration's Office of Advocacy reported last month.

BleachSafe Towel Co. negotiated a larger line of credit in August, but it was only enough to keep the business afloat, not to help fund more hiring, beef up inventory or make other long-term investments.

"Small business is really affected by the bank teller," says Morris E. Sitt, founder of the New York company. "I've never seen banks like this. It's so hard to get the proper financing."

The company is also juggling rising commodity costs. BleachSafe expects its revenue to rise 20% this year, but its cotton costs are up 30%. The company, which has its towels made at a factory in China, is also grappling with the strong Chinese yuan, which is pinching margins.

With these pressures on profit, Mr. Sitt says he's waiting for further improvement in the economy before investing in more workers. BleachSafe, which has 21 employees, recently hired one part-time employee rather than the two full-time salespeople it wanted, and Mr. Sitt cut back on an order for a new spa product he's testing.

"These days, I'd rather take it slow than go out like gangbusters and have a problem six months from now," he says.

Phoenix Products Inc., an Avon Lake, Ohio, faucet maker, is also proceeding with caution, putting hiring, system upgrades and product updates on hold to conserve cash in case of another downturn.

"Things are OK right now, but I'm acting as if we're in the midst of the recession because of all of the economic uncertainty," Phoenix President Raymond Arth says.

His caution stems from recent unemployment and housing-market data, as well as the growing federal deficit. Phoenix's main customers make recreational vehicles and factory-built housing, and if RV buyers get spooked by bad economic news, he worries that orders for his faucets will eventually suffer.

So far, sales are up 7% from a year earlier. But Phoenix's copper costs have increased 35% during the period, and prices for the plastic it uses are also rising. In May, the company pushed through its first price increase in three years, but it's reluctant to raise prices further even though its input costs continue to rise.

"If we increase prices again, we're afraid it will affect sales," Mr. Arth says.

Small companies also aren't as adept at tapping the fast-growing emerging markets that larger companies are relying on to increase sales. Tribute's Mr. Reynolds says he couldn't expand overseas without rewriting all his software first.

"We only sell domestically," Mr. Reynolds says, "so I don't have the opportunity like a public company does to exploit foreign markets that are growing faster."

Write to Dana Mattioli at dana.mattioli@wsj.com and Sarah E. Needleman at sarah.needleman@wsj.com

[admin]

Tengan cuidado con las medicinas genericas, especialmente cuando los ingredientes vienen de China. Las copias no son tan buenas como el original.

China es ahora el mas grande distribuidor de quimicos para la industria farmaceutica - cientos de toneladas al anio - alrededor de todo el mundo. (nos jodimos, eso debe ser una porqueria)


Beware the Risks of Generic Drugs
Copies aren't always as good as the original—especially when ingredients are sourced in China.

By ROGER BATE
Beginning in 2007, tainted heparin (a blood thinner) imported from China was linked to the deaths of 149 American patients. It was a stark example of a growing problem.

China is now the largest supplier of pharmaceutical chemicals—hundreds of tons annually—to the world. And pharmaceutical companies that buy these chemicals do test them. When Illinois-based Baxter Healthcare sourced cheap heparin from China in 2007, for example, it carried out all legally required tests. But the tests it used at the time were unable to detect the contaminant that caused fatal allergic reactions, and the dangerous drug slipped through.

To be sure, the heparin episode was rare; very few problems elude Western companies or the larger of the Indian generics producers. Testing is not nearly as reliable at the smaller companies in India and in emerging markets, and questionable pharmaceuticals have proliferated across the developing world, sometimes with lethal consequences. But even for Western firms, risks do remain, primarily from small, hard-to-detect flaws, such as trace impurities caused by unhygienic practices.

Generics of Neoral, the drug used to decrease the risk of kidney transplant rejection in the United Kingdom, provide an example of the problems that can arise in drug manufacturing. Because of its price (about $250 a month), health administrators tend to favor generic copies. Unfortunately, not all copies of Neoral are exactly equivalent. On average, the copies increase the likelihood of rejection by 10%. As Atholl Johnston, professor of clinical pharmacology at Barts Hospital and the London School of Medicine, recently explained to me, "That's 200 people losing kidneys in the U.K. every year."

Five clinical studies published in the U.S. and abroad show that copycat versions of imatinib mesylate, a leukemia drug, lead to a higher risk of fatality. French researchers found that the composition of 21 of 30 different copies of the chemotherapy drug Taxotere were outside of approved specifications.

And for the past four years, a group of researchers working with me has sampled over 2,000 products from emerging markets. About 5% were substandard—either due to suspect or under-dosed ingredients, or to inappropriate formulations that made the correct ingredients insoluble. (The detailed results have just been published in the British journal Pharmacologia.)

The potential for a large-scale catastrophe in this country is growing. In 2002, the U.S. imported $331 million of pharmaceutical chemicals from China; by 2010, it was $1.74 billion and rising.

By law, Western pharmaceutical firms must buy chemicals solely from certified manufacturing plants. But there are many steps in the production of these chemicals. If certification occurs only at the last stage, it doesn't mean the chemicals are good.

Several pharmaceutical industry experts in China privately indicate that up to 25% of ingredients purchased in China by Western companies come from unknown sources. This is very worrying, because if any of these chemicals were substandard, the products made with them could fail to help patients recover from their illnesses, or even could be lethal.

Lower-quality products also mean more recalls, which can lead to dangerous shortages. The number of times when a desired life-saving drug was unavailable in U.S. hospitals and clinics tripled between 2006 and 2010, to a record 211 cases, according to the University of Utah Drug Information Service. In the first quarter of 2011, 89 incidents were reported.

In China, poor oversight, weak regulation and occasional gross negligence are likely to persist in compromising drug quality. The Chinese drug regulator has an overwhelming task in overseeing a rapidly expanding and already vast industry. The Food and Drug Administration has established an office in China and is increasing investigations of the plants that export to the U.S., but it is woefully understaffed. At best, it can assess each site only once every 13 years.

There are no simple solutions to this problem. With health-care costs escalating, the idea that we should pay even more for drugs by boycotting Chinese suppliers is a tough sell. The FDA must continue to pressure Chinese authorities to test what is on the market and remove any substandard products found. And all companies must provide certification for the entire supply chain of chemicals they buy—not just the final stage of production.

Mr. Bate is a fellow at the American Enterprise Institute.

[admin]

Treasurys Price Chg Yield %
2-Year Note* 4/32 0.427
10-Year Note* 16/32 3.123
* at close

10:02 p.m. EDT 07/05/11Futures Last Change Settle
Crude Oil 97.09 0.20 96.89
Gold 1513.3 0.6 1512.7
DJ Industrials 12536 3 12533
S&P 500 1336.20 -0.80 1336.70

10:13 p.m. EDT 07/05/11Currencies Last (bid) Prior Day †
Japanese Yen (USD/JPY) 80.86 81.07
Euro (EUR/USD) 1.4444 1.4429
† Late Tuesday in New York.

[admin]

Copper July 05,21:19
Bid/Ask 4.3083 - 4.3105
Change -0.0006 -0.01%
Low/High 4.2955 - 4.3111
Charts

Nickel July 05,21:17
Bid/Ask 10.5591 - 10.5927
Change -0.0113 -0.11%
Low/High 10.5478 - 10.6045
Charts

Aluminum July 05,21:19
Bid/Ask 1.1427 - 1.1428
Change -0.0003 -0.03%
Low/High 1.1404 - 1.1463
Charts

Zinc July 05,21:18
Bid/Ask 1.0765 - 1.0783
Change -0.0010 -0.09%
Low/High 1.0739 - 1.0824
Charts

Lead July 05,21:19
Bid/Ask 1.2109 - 1.2131
Change +0.0000 +0.00%
Low/High 1.2091 - 1.2199

[admin]

Mineros acatarán paro nacional de 48 horas a partir de mañana
Martes, 05 de Julio 2011 | 7:22 pm

AND / Trabajadores exigen la promulgación de la Ley que crea el Fondo Complementario de Jubilación Minera que fue aprobada en junio y que ahora ha sido revisada por el congresista Rafael Yamashiro.

La Federación Nacional Minera acatará a partir de mañana un paro nacional de 48 horas en protesta por la reconsideración de la Ley que crea el Fondo Complementario de Jubilación Minera, que fue aprobado por el Congreso de la República el mes pasado.

En un mensaje difundido a través de la página de la FNTMMSP, el secretario general Luis Castillo, responsabiliza al congresista Rafael Yamashiro, por la medida de fueerza calificándolo de desleal y prepotente pues por segunda vez, "quiere bloquear la ley que busca favorecer a todos los trabajadores de ese sector".

"Llamamos a la reflexión a los miembros de la bancada de Unidad Nacional porque creemos que ellos no están para perjudicar el país y tampoco están de acuerdo, nos parece, con la actitud del congresista y que al final de esta legislatura quiere bloquear el proyecto aprobado y que ahora es ley", manifestó.

Castillo hizo un llamado a los trabajadores del sector minero, para que se puedan plegarse a esta medida de fuerza. Afirmó que ellos actuarán dentro del marco de la ley, "pero sí con la fuerza necesaria para hacer cumplir nuestros derechos".

Los mineros se congregarán en la Plaza Bolognesi, a partir de las 9 y 30 de la mañana, para marchar al Parlamento y luego dirigirse al domicilio del congresista aludido y pedirle que retire la observación.

[Victor VE]

Admin, no solo China preocupa con sus medicamentos o los insumos de los mismos, tambien los indios con sus medicamentos, son terribles, y no solo eso, sino tambien el envase en que van dichos medicamentos. En el caso de China para envasar ampollas, viales o frascos roscados utilizan para la fabricación de los mismos un vidrio de baja calidad, mayormente alcalino, cuando deberia ser neutro, lo cual podria alterar la alcalinidad del medicamento. Si esto sucede y se inyecta en la sangre o en el cuerpo podria hasta morir el paciente. Lo digo porq antes trabajaba en una empresa que fabrica ese tipo de envases localmente y teniamos que competir contra ellos. En muchos casos utilizan Vidrio tipo II o III cuando deberian utilizar el tipo I, uno se corre el riesgo.

En el sector salud del Estado muchas licitaciones son ganados por distribuidores de medicamentos chinos o indios, aca muchos de ellos hacen el pedido directamente al laboratorio en esos paises y se los mandan ya en cajas para su distribucion local.

[Orlando]

("Los mercados globales: Las acciones europeas inferior; Bancos Pesar", en 0808 GMT, equivocadamente en el día en cuestión en el primer párrafo la versión correcta la siguiente:.)



- Las acciones europeas más baja después de la calificación de Moody crediticia de Portugal

- El contagio de la deuda soberana teme resurgir

- Los bancos sufren la peor parte de la venta de

- Mercado anticipa que el BCE, las decisiones BOE caso, las nóminas no agrícolas


Por Michele Maatouk

De Dow Jones Newswires


LONDRES (Dow Jones) - Las acciones europeas estaban en baja el miércoles, con acciones de los bancos bajo presión por los temores renovados sobre la exposición del sector a la deuda soberana después de Moody bajó la calificación crediticia de Portugal.

En 0750 GMT, el índice Stoxx Europe 600 bajó un 0,4% a 274,51. FTSE 100 de Londres bajó 0,5% a 5.996,87, el DAX de Francfort cayó un 0,2% a 7.426,37 y en París el CAC-40 fue del 0,4% inferior a 3.962,22. PSI 20 de Portugal significativamente rendimiento inferior de sus pares europeos, un 2,1% a 7.192,48.

La noche del martes, la agencia Moody 's Investors rebajar la calificación de deuda soberana de Portugal por cuatro escalones a Ba2 - dos niveles en el territorio de chatarra - y poner al país en vigilancia negativa, es decir, rebajas son posibles nuevas. Moody también dijo que espera que Portugal a necesitar un rescate segundos.

Esta última rebaja plantea la cuestión de quién será el próximo, dijeron operadores. "A pesar de Irlanda hasta el momento ha conseguido mantener su estatus de grado de inversión, los riesgos de contagio se pone de relieve este último movimiento calificaciones de Moody", dijo Goodbody Stockbrokers,. Señaló que Moody en la actualidad tiene a Irlanda en Baa3 con perspectiva negativa, que es el grado de inversión más baja, mientras que la Fitch y Standard & Poor tienen el derecho soberano nominal ligeramente superior a BBB +.

Como resultado, los bancos fueron los de peor desempeño, con el índice Stoxx Europe 600 para el sector un 1,6% a 185,09. La reunión del miércoles de los principales bancos europeos en París, es probable que sea en el centro de atención dada último movimiento Moody en Portugal. Los bancos se reúnen para discutir participación del sector privado en un plan de rescate para Grecia.

El objetivo principal de esta semana será el Banco Europeo del jueves Central y el Banco de Inglaterra tasa de interés de las decisiones, así como los datos no agrícolas del viernes nóminas.

Antes de eso, la versión final del primer trimestre de la zona euro los datos del producto interno bruto se debe a las 0900 GMT del miércoles. Alemania los pedidos industriales se deben a las 1000 GMT y los EE.UU. las cifras del ISM no manufacturero son a las 1400 GMT.

En Asia, los mercados bursátiles se mezclaron miércoles cotiza en Hong Kong los bancos de China que cae sobre las noticias Temasek Holdings de Singapur levantó $ 3,62 mil millones con la venta por sus participaciones en el Banco de China y China Construction Bank Corp.

Japón Nikkei de la Bolsa de subió un 0,2%, S de Australia & P / ASX 200 ganó un 0,1% y el Kospi de Corea del Sur compuesto plana. El índice Shanghai Composite cayó un 0,8%, el Hang Seng de Hong Kong Índice perdió 0,4% y el principal índice de Taiwán subió un 0,4%.

Un espectáculo empapado en Wall Street el martes y fresco de la zona euro de la deuda soberana preocupa a muchos inversores mantienen al margen. Mientras que los últimos datos de la mejora de fabricación de EE.UU. han aliviado las preocupaciones sobre las perspectivas de la economía más grande del mundo, los participantes del mercado se mantienen cautelosos.

En los mercados de divisas europeos, el euro retrocedió frente al dólar otra vez en los problemas de deuda soberana. Por 0750 GMT, el euro se negociaba a 1,4366 dólares, de 1,4426 dólares la noche del martes en Nueva York. El dólar estaba a Y80.92 de Y81.10.

Entre los productos de oro al contado estaba a 1,517.20 dólares por onza troy, en alza de 1,40 dólares en Nueva York. Agosto Nymex de futuros del petróleo crudo bajaron 4 centavos, a 96,85 dólares por barril.

En los mercados de bonos de septiembre bund contrato de futuros subió 0,58 a 126,20.


-Por Michele Maatouk, Dow Jones Newswires, +44-20-7842-9447; michele.maatouk @ dowjones.com


(END) Dow Jones Newswires

06 de julio 2011 04:14 ET (08:14 GMT)

[admin]

Admin, no solo China preocupa con sus medicamentos o los insumos de los mismos, tambien los indios con sus medicamentos, son terribles, y no solo eso, sino tambien el envase en que van dichos medicamentos. En el caso de China para envasar ampollas, viales o frascos roscados utilizan para la fabricación de los mismos un vidrio de baja calidad, mayormente alcalino, cuando deberia ser neutro, lo cual podria alterar la alcalinidad del medicamento. Si esto sucede y se inyecta en la sangre o en el cuerpo podria hasta morir el paciente. Lo digo porq antes trabajaba en una empresa que fabrica ese tipo de envases localmente y teniamos que competir contra ellos. En muchos casos utilizan Vidrio tipo II o III cuando deberian utilizar el tipo I, uno se corre el riesgo.

En el sector salud del Estado muchas licitaciones son ganados por distribuidores de medicamentos chinos o indios, aca muchos de ellos hacen el pedido directamente al laboratorio en esos paises y se los mandan ya en cajas para su distribucion local.

Es alrededor de todo el mundo Victor, no solo en el Peru, por eso mejor hay que hacer el esfuerzo y comprar las medicinas originales, en caso sea una enfermedad seria. Si no se tiene seguro de salud, hay que ahorrar mensualmente una cantidad aunque sea pequenia para ese rubro, una cuenta separada es la mejor opcion.

[admin]

Treasurys Price Chg Yield %
2-Year Note 0/32 0.427
10-Year Note 3/32 3.114
* at close

6:37 a.m. EDT 07/06/11Futures Last Change Settle
Crude Oil 96.36 -0.53 96.89
Gold 1513.7 1.0 1512.7
DJ Industrials 12489 -44 12533
S&P 500 1331.60 -5.10 1336.70

6:31 a.m. EDT 07/06/11Currencies Last (bid) Prior Day †
Japanese Yen (USD/JPY) 80.99 81.07
Euro (EUR/USD) 1.4363 1.4429
† Late Tuesday in New York.

[admin]

China aumentara sus intereses en 25 puntos basicos, es el tercer aumento este anio.

[admin]

El downgrade de Portugal por parte de Moody's tiene a Europa a la baja, el Asia cerro mixta.